Clinical Trial Update: The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety and preliminary efficacy of sequential Ropeginterferon alfa-2b (P1101) followed by an anti-PD-1 agent in interferon-naiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Hepatitis D

Drugs mentioned

• Anti-PD1 monoclonal antibody (anti-PD-1 monoclonal antibody)
• Ropeginterferon alfa-2b (P1101) (ropeginterferon alfa-2b)

Snippet

Sponsor: PharmaEssentia | Conditions: Chronic Hepatitis B Infection, Chronic Hepatitis D Infection | Phase 1 | Status: COMPLETED